GlassScriptPhysician profile
Sumeet Chandra
NPI 1801853171
$16,441.57
in general payments reported to CMS, 2019-2025
77 companies · $1,843 in 2025
The $1,843 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,364 · 2020: $2,308 · 2021: $2,971 · 2022: $2,860 · 2023: $2,074 · 2024: $2,020 · 2025: $1,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,705 · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,705.11 |
| Education | $232.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,353.89 | 2019-2025 | |
| Pfizer INC. | $1,219.84 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,081.25 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $949.49 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $925.12 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Amgen INC. | $745.82 | 2019-2023 | Blincyto, Kyprolis, Vectibix |
| E.R. Squibb & Sons, L.L.C. | $732.53 | 2019-2025 | Opdivo |
| Celgene Corporation | $646.13 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Seagen INC. | $612.94 | 2019-2023 | Adcetris, Padcev |
| Astellas Pharma US INC | $533.12 | 2019-2025 | Vyloy, Xtandi, Padcev |
| Incyte Corporation | $524.67 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Genzyme Corporation | $487.73 | 2019-2025 | |
| Lilly USA, LLC | $479.03 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Genentech USA, INC. | $444.15 | 2019-2024 | Polivy, Gazyva, Phesgo |
| Daiichi Sankyo INC. | $424.50 | 2019-2025 | Enhertu, Injectafer |
Show all 76 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumeet Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.